Company intelligenceJNJ
Johnson & Johnson
NYSE · Pharmaceutical Preparations
Q2 FY2026Quarter ended Jun 28, 2026 (13-week quarter)Data as of Oct 13, 2026
This quarter's figures come from the company's SEC filing.
Blockhaven company read
Revenue grew 6.6% year over year, slowing from 9.9% in the prior quarter.
Margins were roughly stable year over year.
Business trendDeceleratingRevenue growth slowed; gross margin was roughly steady and GAAP net income was roughly steady.
Latest reported quarter
13-week quarter
RevenueGAAP
- Latest
- $25.3 billion
- Year ago
- $23.7 billion
- Change
- +6.6% (Up year over year)
Gross profitGAAP
- Latest
- $17.3 billion
- Year ago
- $16.1 billion
- Change
- +7.1% (Up year over year)
Net incomeGAAP
- Latest
- $5.53 billion
- Year ago
- $5.54 billion
- Change
- −0.05% (Down year over year)
Diluted EPSGAAP
- Latest
- $2.27
- Year ago
- $2.29
- Change
- −0.9% (Down year over year)
Diluted sharesGAAP
- Latest
- 2.44 billion
- Year ago
- 2.42 billion
- Change
- +0.9% (Up year over year)
Operating cash flowGAAP
- Latest
- $8.62 billion
- Year ago
- $3.88 billion
- Change
- +122.2% (Up year over year)
Derived from year-to-date filings
Capital expendituresGAAP
- Latest
- $1.32 billion
- Year ago
- $1.04 billion
- Change
- +26.6% (Up year over year)
Derived from year-to-date filings
Cash and equivalentsGAAP
- Latest
- $20.4 billion
- Year ago
- $18.6 billion
- Change
- +9.9% (Up year over year)
| Measure | Basis | Latest quarter | Year ago | Change |
|---|---|---|---|---|
| Revenue | GAAP | $25.3 billion | $23.7 billion | +6.6% (Up year over year) |
| Gross profit | GAAP | $17.3 billion | $16.1 billion | +7.1% (Up year over year) |
| Net income | GAAP | $5.53 billion | $5.54 billion | −0.05% (Down year over year) |
| Diluted EPS | GAAP | $2.27 | $2.29 | −0.9% (Down year over year) |
| Diluted shares | GAAP | 2.44 billion | 2.42 billion | +0.9% (Up year over year) |
| Operating cash flowDerived from year-to-date filings | GAAP | $8.62 billion | $3.88 billion | +122.2% (Up year over year) |
| Capital expendituresDerived from year-to-date filings | GAAP | $1.32 billion | $1.04 billion | +26.6% (Up year over year) |
| Cash and equivalents | GAAP | $20.4 billion | $18.6 billion | +9.9% (Up year over year) |
This quarter's figures come from the company's SEC filing. GAAP unless labelled. Non-GAAP and company-defined measures are labelled.
Growth and margins
Revenue growth
+6.6%
Decelerating versus +9.9% in the prior quarter (year over year, GAAP).
Margins (GAAP)
- Gross margin 68.2%Roughly stable +32 bp vs 67.9% a year ago
- Net margin 21.9%Compressed −146 bp vs 23.3% a year ago
Guidance
StatusNone found in the latest release
Sources and dates
Filings and dates
- SEC filings (10-Q, 10-K financial data)
- Data as of Oct 13, 2026. Quarter ended Jun 28, 2026.
Data health
Figures cross-checked against SEC filings.
- SEC company recordAvailable
- SEC financial dataAvailable
- Earnings releaseUnavailable
Descriptive company facts from SEC filings and the issuer's own earnings release. GAAP figures are labelled as such. Not investment advice, a rating or a recommendation. Disclosures